MaxCyte Stock Performance
| MXCT Stock | USD 0.76 -0.01 -1.01% |
The firm holds a Beta (Systematic Risk) of 0.47, which attests to generally lower market sensitivity than the broad market. With a sub-1 beta, MaxCyte typically participates in market rallies at a reduced pace while often limiting downside exposure. At this point, MaxCyte has a negative expected return of -1.08%.
Risk-Adjusted Performance
Weak
Weak | Strong |
During the last 90 trading days, MaxCyte produced negative risk-adjusted performance, which signals weak return efficiency for investors with long positions. The result matters because weak risk-adjusted return can persist even when isolated price moves briefly look constructive. In spite of unfluctuating performance in the last few months, the stock's fundamental indicators remain comparatively stable, which may send shares a bit higher in April 2026. The newest uproar may also be a sign of mid-term up-swing for the firm's private investors. Learn More
1 | Day Trade Is Max Cyte Inc stock affected by interest rate hikes - Oil Prices Safe Entry Momentum Stock Tips - moha.gov.vn | 01/13/2026 |
2 | Acquisition by Collins Cynthia of 97698 shares of Max Cyte at 3.87 subject to Rule 16 b-3 | 01/29/2026 |
3 | Max Cyte Stock Crosses Below 50-Day Moving Average Heres Why | 02/04/2026 |
4 | Acquisition by Collins Cynthia of 29210 shares of Max Cyte subject to Rule 16 b-3 | 02/06/2026 |
5 | Max Cyte Upgraded at Wall Street Zen | 02/10/2026 |
6 | Max Cyte unveils Ex PERT DTx, a 96-well electroporation platform to accelerate discovery | 02/24/2026 |
7 | Max Cyte, Inc. Receives Average Rating of Hold from Analysts - Market Beat | 03/02/2026 |
8 | Disposition of 10142 shares by Swirsky Douglas J of Max Cyte at 0.815 subject to Rule 16 b-3 | 03/17/2026 |
9 | Max Cyte launches Ex PERT DTx platform to accelerate high-throughput drug discovery - MSN | 03/20/2026 |
| Begin Period Cash Flow | 46.5 M | |
| Total Cashflows From Investing Activities | 6.9 M |
Relative Risk vs. Return Landscape
If you had invested $ 155.00 in MaxCyte on December 23, 2025 and sold it today you would have lost $ 79.00 from holding MaxCyte or given up 50.97% of portfolio value over 90 days. MaxCyte does not currently generate positive expected returns and carries 3.6064% risk (volatility on return distribution) over a 90-day horizon. In different words, 32% of stocks are less volatile than MaxCyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
The concept of mean reversion, where MaxCyte Stock price gravitates toward equilibrium, is fundamental to market analysis. This pattern is a cornerstone of many forecasting models, though periods of persistent mispricing occur. Investors demand compensation for the additional risk inherent in stocks that remain mispriced longer. The concept of price convergence is essential context for any investor forecasting MaxCyte Stock price direction.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 0.76 | 90 days | 0.76 | about 82.62 |
Statistical modeling indicates that the probability of MaxCyte moving above the current price in 90 days from now is about 82.62 . The model uses historical price data to estimate the range of likely outcomes for this stock. The estimate assumes relatively stable market conditions and may not account for tail risk events. The statistical approach provides context that complements fundamental and technical analysis. (This stock probability density function maps the likelihood of MaxCyte Stock reaching different price levels over 90 days). Taller, narrower curves suggest lower volatility and more concentrated price expectations for MaxCyte Stock. Review this distribution alongside MaxCyte Stock's implied volatility for additional context. Review this distribution before making position sizing or risk management decisions around MaxCyte Stock.
MaxCyte Price Density |
| Price |
Predictive Modules for MaxCyte
Accurately predicting the stock market is one of the most challenging tasks for investors analyzing MaxCyte. No single approach dominates, but the practice of forecasting remains an essential element of the investment process. Investors benefit from applying a variety of techniques rather than relying on a single model for MaxCyte. The practice of comparing forecasts for MaxCyte builds analytical resilience regardless of which model proves most accurate.Experienced investors tracking MaxCyte's watch for mean reversion setups where price has deviated from its long-run average. Sentiment extremes, news events, or liquidity shocks are common catalysts for these temporary dislocations in MaxCyte. Prices periodically overshoot their intrinsic value in both directions, creating mean reversion opportunities in MaxCyte. The mean reversion signal is most useful when combined with fundamental confirmation for MaxCyte's.
Primary Risk Indicators
Volatility has been a defining feature of the stock market in recent decades, and MaxCyte has reflected that pattern. Sudden corrections and sharp rallies have tested many portfolios that include MaxCyte. A risk management approach built around MaxCyte's volatility metrics can help investors manage downside exposure. Tracking MaxCyte's risk indicators over time reveals how the risk profile evolves across market cycles.α | Alpha over Dow Jones | -0.8895 | |
β | Beta against Dow Jones | 0.47 | |
σ | Overall volatility | 0.33 | |
Ir | Information ratio | -0.2231 |
Investor Alerts and Insights
For investors following MaxCyte, automated alerts provide early signals of meaningful shifts in stock dynamics. MaxCyte notifications highlight material changes that could affect portfolio decisions and overall risk exposure. Investors can customize MaxCyte alert parameters to match their risk tolerance and investment horizon. Pairing alerts with independent analysis strengthens conviction in MaxCyte investment decisions.| MaxCyte generated a negative expected return over the last 90 days | |
| MaxCyte has some characteristics of a very speculative penny stock | |
| MaxCyte has high historical volatility and very poor performance | |
| MaxCyte has high likelihood to experience some financial distress in the next 2 years | |
| The company reported previous year's revenue of 38.63 M. Net Loss for the year was -41.05 M with profit before overhead, payroll, taxes, and interest of 27.53 M. | |
| MaxCyte currently holds about 240.89 M in cash with -27.61 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Max Cyte launches Ex PERT DTx platform to accelerate high-throughput drug discovery - MSN |
Price Density Drivers
For MaxCyte, price shifts are largely a function of buyer and seller positioning dynamics and broader market conditions. Key market indicators for MaxCyte Stock are presented below to contextualize recent price movements. Tracking MaxCyte's market indicators provides context for distinguishing fundamental shifts from short-term noise. This data helps frame whether current MaxCyte's price movements warrant further investigation.
| Common Stock Shares Outstanding | 104.8 M | |
| Cash And Short Term Investments | 154.5 M |
MaxCyte Fundamentals Growth
The pricing of MaxCyte Stock is heavily influenced by MaxCyte's fundamental performance over time. Investors monitor revenue growth, profit margins, cash flow generation, and debt management as key indicators. The performance of MaxCyte Stock is closely linked to MaxCyte's underlying financial metrics and growth rates. Profitability trends, cash flow generation, and capital structure remain the key fundamentals for MaxCyte Stock.
| Return On Equity | -0.23 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | -1.33 % | |||
| Operating Margin | -1.62 % | |||
| Current Valuation | -5.94 M | |||
| Shares Outstanding | 106.67 M | |||
| Price To Book | 0.45 X | |||
| Price To Sales | 2.37 X | |||
| Revenue | 38.63 M | |||
| Gross Profit | 27.53 M | |||
| EBITDA | -46.41 M | |||
| Net Income | -41.05 M | |||
| Cash And Equivalents | 240.89 M | |||
| Cash Per Share | 2.37 X | |||
| Total Debt | 18.03 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 14.24 X | |||
| Book Value Per Share | 1.69 X | |||
| Cash Flow From Operations | -27.61 M | |||
| Earnings Per Share | -0.43 X | |||
| Market Capitalization | 81.63 M | |||
| Total Asset | 239.47 M | |||
| Retained Earnings | -216.85 M | |||
| Working Capital | 155.91 M | |||
Performance Metrics & Calculation Methodology
MaxCyte performance is measured on a risk-adjusted basis against benchmarks. Relative performance helps interpret behavior versus benchmarks or category peers. MaxCyte shows ROE of -23.19%, ROA of -13.67%.
For MaxCyte, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Intraday timing differences may exist. Return and risk statistics are calculated from historical price series.